The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.g

Pulmonary fibrosis

Publications

Rathi M, Ramachandran R, Gundlapalli S, Agarwal R, Das A, Kumar V, Kohli HS, Jha V, Sakhuja V

Rituximab induced pulmonary fibrosis in a patient with lupus nephritis.

Lupus. 2012;21(10):1131-4

Vulsteke C, Dierickx D, Verbeken E, Wolter P, Thomas J, Schöffski P

Rituximab-induced fatal interstitial pneumonitis: case report.

Leukemia & lymphoma. 2010;51(3):546-8

Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P

The late adverse events of rituximab therapy--rare but there!

Leukemia & lymphoma. 2009;50(7):1083-95

Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, Deschênes G

Fatal pulmonary fibrosis after rituximab administration.

Pediatric nephrology (Berlin, Germany). 2009;24(9):1753-5

Leon RJ, Gonsalvo A, Salas R, Hidalgo NC

Rituximab-induced acute pulmonary fibrosis.

Mayo Clinic proceedings. 2004;79(7):949, 953